Toremifene-d6 (hydrochloride)

Toremifene-d6 (hydrochloride)

• UNSPSC Description: Toremifene-d6 (Z-Toremifene-d6) hydrochloride is deuterium labeled Toremifene. Toremifene is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively[1][2].
• Target Antigen: Estrogen Receptor/ERR; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Others;Vitamin D Related/Nuclear Receptor
• Applications: COVID-19-immunoregulation
• Field of Research: Infection
• Solubility: 10 mM in DMSO
• Smiles: ClCC/C(C1=CC=CC=C1)=C(C2=CC=CC=C2)\C3=CC=C(C=C3)OCCN(C([2H])([2H])[2H])C([2H])([2H])[2H].[H]Cl
• Molecular Weight: 448.46
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Matthew R Smith, Selective Estrogen Receptor Modulators to Prevent Treatment-Related Osteoporosis.Rev Urol. 2005; 7(Suppl 3): S30-S35.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported